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Activation of immune cells is regulated by posi-
tive  and  negative  signals  transmitted  by  cell   
surface immunoreceptors. The immunorecep-
tor tyrosine-based activation motif (ITAM)–
bearing adapters, including the CD3, , , and 
 subunits of the T cell receptor, the Ig (CD79a) 
and Ig (CD79b) of the B cell receptor (BCR), 
FcRI, and DAP12, play a central role in   
mediating activation signals in lymphoid and 
myeloid cells (Humphrey et al., 2005). These 
ITAM-bearing adapters contain an acidic amino 
acid  (aspartic  acid)  in  their  transmembrane 
domains and noncovalently associate with cell 
surface immunoreceptors that contain a basic 
amino acid (arginine or lysine) in their transmem-
brane domains. In contrast to the CD3, TCR, 
and BCR subunits that are expressed only by 
lymphocytes, FcRI and DAP12 are broadly 
expressed in myeloid cells and NK cells.
DAP12 (Olcese et al., 1997; Lanier et al., 
1998; Tomasello  et  al.,  1998)  associates  with 
several cell surface receptors, including mem-
bers of the human KIR (killer cell immuno-
globulin-like receptor) gene family, mouse Ly49 
gene family, human NKp44, and human and 
mouse CD94-NKG2C heterodimeric proteins 
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DAP12, an immunoreceptor tyrosine-based activation motif–bearing adapter protein, is 
involved in innate immunity mediated by natural killer cells and myeloid cells. We show 
that DAP12-deficient mouse B cells and B cells from a patient with Nasu-Hakola disease,  
a recessive genetic disorder resulting from loss of DAP12, showed enhanced proliferation 
after stimulation with anti-IgM or CpG. Myeloid-associated immunoglobulin-like receptor 
(MAIR) II (Cd300d) is a DAP12-associated immune receptor. Like DAP12-deficient B cells, 
MAIR-II–deficient B cells were hyperresponsive. Expression of a chimeric receptor com-
posed of the MAIR-II extracellular domain directly coupled to DAP12 into the DAP12-
deficient or MAIR-II–deficient B cells suppressed B cell receptor (BCR)–mediated 
proliferation. The chimeric MAIR-II–DAP12 receptor recruited the SH2 domain–containing 
protein tyrosine phosphatase 1 (SHP-1) after BCR stimulation. DAP12-deficient mice 
showed elevated serum antibodies against self-antigens and enhanced humoral immune 
responses against T cell–dependent and T cell–independent antigens. Thus, DAP12-coupled 
MAIR-II negatively regulates B cell–mediated adaptive immune responses.
© 2011 Nakano-Yokomizo et al.  This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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receptors in macrophages and plasmacytoid den-
dritic cells (Fuchs et al., 2005; Blasius et al., 2006; 
Hamerman et al., 2006; Turnbull et al., 2006).
Loss of function in DAP12 or TREM-2 as 
a result of mutations in the TYROBP gene or 
TREM2 gene, respectively, is responsible for a re-
cessive genetic disorder named Nasu-Hakola dis-
ease or polycystic lipomembranous osteodysplasia 
with  sclerosing  leukoencephalopathy  (Paloneva 
et al., 2000, 2002). These patients at adolescence present prob-
lems with bone development and, later, dementia as a re-
sult of plaque formation in the central nervous system (CNS; 
Kaneko et al., 2010). Osteoclasts in the bone and microglial 
cells in the CNS expressing DAP12 and TREM-2 are derived 
from myeloid cell precursors, and defective function of these 
cells as a result of DAP12 or TREM-2 deficiency causes the 
phenotype manifested in the disease (Cella et al., 2003;   
Paloneva et al., 2003).
MAIR-II (Yotsumoto et al., 2003; also named LMIR-2 
[Kumagai et al., 2003], CLM-4 [Chung et al., 2003], DIgR1 
[Luo et al., 2001], or Cd300d) is a member of a multigene 
family consisting of nine genes on a small segment of mouse 
chromosome 11 (Chung et al., 2003; Nakano et al., 2008). 
MAIR family genes are homologous to the human CD300 
family, which is located on human chromosome 17 (Clark 
et al., 2001) in a region syntenic to mouse chromosome 11. 
MAIR-II is expressed on macrophages in the peritoneal cavity 
and a subset of B cells in the spleen. We and others have 
demonstrated that DAP12 is not only expressed by NK cells and 
myeloid cells but also by human and mouse B cells (Tomasello 
et al., 1998; Yotsumoto et al., 2003). MAIR-II associates with 
DAP12 in B cells as well as myeloid cells (Yotsumoto et al., 
2003; Nakahashi et al., 2007), although MAIR-II also asso-
ciates with FcRI in peritoneal macrophages (Nakahashi   
et al., 2007). Upon cross-linking with a monoclonal anti-
body, MAIR-II initiates activation signals in macrophages   
resulting in the production of proinflammatory cytokines 
TNF and IL-6 (Kumagai et al., 2003; Yotsumoto et al., 2003;   
on NK cells and numerous human and mouse activating re-
ceptors expressed on myeloid cells. The receptors expressed 
by myeloid cells include the triggering receptor expressed on 
myeloid cells (TREM) 1, TREM-2, TREM-3, myeloid- 
associated immunoglobulin-like receptor (MAIR) II (also 
known as CD300d), CD200RLa, SIRP-, PILR-, MDL-1, 
and others (Lanier, 2009). Upon ligand binding, these DAP12-
coupled immunoreceptors are triggered to mediate intracel-
lular activation signals via the ITAM of DAP12, which is 
tyrosine phosphorylated by Src family kinases and recruits 
Syk or ZAP70. This results in the tyrosine phosphorylation of 
these kinases and downstream signaling for activation of cyto-
toxicity and cytokine secretion by NK cells and/or myeloid 
cells, including monocytes, macrophages, microglial cells, 
dendritic cells, mast cells, basophils, eosinophils, and neutro-
phils (Lanier and Bakker, 2000; Tomasello and Vivier, 2005; 
Lanier, 2009).
DAP12 can also transmit inhibitory signals in myeloid 
cells (Hamerman et al., 2005; Barrow and Trowsdale, 2006; 
Turnbull and Colonna, 2007; Underhill and Goodridge, 2007; 
Blank et al., 2009; Ivashkiv, 2009; Peng et al., 2010), although 
these  signaling  pathways  are  not  completely  understood. 
DAP12-deficient  macrophages  and  dendritic  cells  in  mice 
show  increased  production  of  proinflammatory  cytokines, 
such as IL-6 and IL-12, in response to activation by toll-like 
receptor (TLR) ligands (Hamerman et al., 2005; Chu et al., 
2008).  Further  studies  have  identified  human  and  mouse 
TREM-2, mouse Siglec (sialic acid–binding immunoglobulin-
like lectin) H, and human NKp44 as inhibitory DAP12-coupled 
Figure 1.  Enhanced proliferation of DAP12-deficient 
B cells in response to anti-IgM and CpG. B cells were 
purified from spleens of WT or DAP12-deficient (DAP12 
KO) mice by positive selection using magnetic beads coated 
with anti-B220 mAb (A), followed by cell sorting using 
flow cytometry (E), and were analyzed by flow cytometry. 
Representative data of the B cell purification from WT mice 
are shown (A and E). The purified B cells were stained or 
not with CFSE and stimulated with F(ab’)2 fragments of 
anti-IgM, CpG, or LPS. Proliferation was analyzed by BrdU 
incorporation (B and F) or flow cytometry (D). Anti-IgM at 
3 µg/ml and CpG at 0.06 µM were used for stimulation in 
D. Culture supernatants were assayed for IL-6 production 
by ELISA (C and G). The proliferation assays shown in  
B, D, and F were done using B cells isolated by magnetic 
beads alone or by flow cytometry, respectively. *, P < 0.05; 
**, P < 0.01. Data are representative of more than three 
independent experiments. Error bars show SD.JEM Vol. 208, No. 8 
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indirectly to the stimuli through inflammatory cytokines pro-
duced by these macrophages. To test this possibility, we pre-
pared B cells from the spleen with a purity of >99.9% by 
sorting with flow cytometry (Fig. 1 E) and then stimulated 
these B cells with anti-BCR mAb or CpG. The results were 
similar to those obtained when using cells purified by mag-
netic beads (Fig. 1 F), indicating that the purified B cells de-
rived from DAP12-deficient mice responded to stimulation 
with anti-BCR mAb, TLR-4, and TLR-9 ligands significantly 
more than did B cells from WT mice.
We next purified follicular (IgMlow, CD23+, AA4, and 
B220+), marginal zone (IgMhigh, CD23, AA4, and B220+), 
and transitional (IgM+, AA4+, and B220low) B cells (Allman   
et al., 2001) from the spleens of WT and DAP12-deficient 
mice by flow cytometry. These purified B cells were labeled 
with CFSE and stimulated with anti-BCR mAb. We found that 
DAP12-deficient B cells in all subsets responded to anti-BCR 
stimulation significantly more than did WT B cells (Fig. S1), 
indicating that the negative regulation by DAP12 is not re-
stricted to any specific B cell subset but rather is globally 
involved in B cell proliferation induced by BCR stimulation.
There were no differences between WT and DAP12- 
deficient B cells in cell surface expression of differentiation, 
maturation, and activation markers, including IgM, IgD, CD80, 
CD86, I-Ab, CD40, CD69, CD23, CD38, CD25, and CD95 
(Fig. S2). Thus, it is unlikely that macrophages had affected the 
B  cell  maturation  or  activation  status  in  DAP12-deficient 
mice and indirectly enhanced the proliferation of B cells in 
response to these stimuli in vitro. To strictly exclude this pos-
sibility, however, we generated BM chimeric mice by transfer 
of a 1:1 mixture of BM cells from CD45.1 WT mice and   
either  CD45.2 WT  or  DAP12-deficient  mice  into  Rag1- 
deficient mice, which lack mature B and T lymphocytes 
(Fig. 2 A). CD45.1+ WT B cells and CD45.2+ WT or DAP12-
deficient B cells were sorted to >99.9% purity from the spleen 
of each BM chimeric mouse (Fig. 2 B) and then stimulated 
with CpG. The CD45.1+ and CD45.2+ WT B cells derived 
from the CD45.1 WT + CD45.2 WT BM chimeric mice 
Nakahashi et al., 2007). However, the direct role of DAP12 
and MAIR-II in B cell activation has not been elucidated.
In this study, we investigated the role of DAP12 in B cell 
activation. We report that restoration of DAP12 in mouse and 
human DAP12-deficient B cells from Tyrobp/ mice and a 
patient  with  Nasu-Hakola  disease,  respectively,  suppressed   
B cell proliferation after stimulation of the BCR or TLR-9. 
We generated Cd300d/ mice deficient in MAIR-II ex-
pression and present evidence that MAIR-II is the DAP12-
associated receptor responsible for this inhibitory function.
RESULTS
Enhanced proliferation of DAP12-deficient B cells
To investigate the function of DAP12 in B cells, we purified 
B cells from the spleens of WT and DAP12-deficient mice to 
a purity of >95% by sorting with magnetic beads (Fig. 1 A). 
We then examined the role of DAP12 in B cell proliferation 
induced by the stimulation of BCR, TLR-4, or TLR-9. When 
the purified B cells were stimulated with anti-BCR mono-
clonal antibody (anti-IgM mAb), LPS (a TLR-4 ligand), or 
CpG  (a TLR-9  ligand),  proliferation  of  DAP12-deficient   
B cells, as determined by BrdU incorporation, increased 
significantly more than that of WT B cells in response to 
these stimuli (Fig. 1 B). Moreover, DAP12-deficient B cells 
treated  with  CpG  produced  significantly  higher  amounts   
of IL-6 than did WT B cells (Fig. 1 C), although we did not 
detect IL-6 production after stimulation of the B cells with 
anti-IgM  mAb. The  increased  proliferation  of  DAP12- 
deficient B cells in response to anti-IgM mAb and CpG was 
also shown by using a cell division assay with CFSE-labeled 
B cells (Fig. 1 D).
Previous results have demonstrated that macrophages de-
rived from DAP12-deficient mice produce inflammatory cyto-
kines at significantly higher levels than those from WT mice 
in response to TLR stimulation, such as by LPS, CpG, or lipo-
peptide (Hamerman et al., 2005), raising the possibility that 
the preparation of DAP12-deficient B cells contained con-
taminating DAP12-deficient macrophages and responded   
Figure 2.  Enhanced proliferation of DAP12-deficient B cells derived from BM chimeric mice in responses to CpG. (A) BM chimeric mice were 
generated by adoptive transfer of an equal number of BM cells isolated from CD45.1 WT mice and either CD45.2 WT or DAP12-deficient mice into Rag1-
deficient mice. (B) CD45.1+ WT B cells and CD45.2+ WT or DAP12-deficient B cells were then sorted to >99.9% purity from spleens of mixed BM chimeric 
mice and were analyzed by flow cytometry. (C) The purified B cells were stimulated with CpG for 48 h. Proliferation was analyzed by BrdU incorporation. 
**, P < 0.01. Data are representative of three independent experiments. Error bars show SD.1664 DAP12 suppresses B cell–mediated responses | Nakano-Yokomizo et al.
Syk, Akt, and Erk phosphorylation after stimulation of BCR 
with F(ab’)2 fragments of anti-IgM mAb, the levels of phos-
phorylation were greater in DAP12-deficient B cells than in 
WT B cells (Fig. 3 A). In contrast, the kinetics and levels of 
Jnk and p38 phosphorylation were comparable between   
WT and DAP12-deficient B cells (Fig. S3 A). We also mea-
sured the kinetics and magnitude of tyrosine phosphorylation 
of Akt and Erk in WT and DAP12-deficient B cells after stim-
ulation with CpG. Similar to the case of B cells stimulated 
with anti-IgM, Akt and Erk showed a greater increase in 
phosphorylation in DAP12-deficient B cells than in WT   
B cells (Fig. 3 B). Collectively, these results suggest that the 
MAPK and PI3K pathways interact with the DAP12 signal 
pathway to suppress B cell proliferation induced by BCR and 
TLR-9 stimulation.
BCR stimulation activates the NF-B pathway through 
Akt activation in B cells, which results in induction of Bcl-xL 
and  enhanced  proliferation  of  B  cells  (Kane  et  al.,  1999;   
Suzuki et al., 2003). Because we observed enhanced Akt acti-
vation after stimulation with CpG, as well as anti-IgM, in 
were comparable to each other to the extent of proliferation 
induced by stimulation with CpG. In contrast, CD45.2+ 
DAP12-deficient B cells from the CD45.1 WT + CD45.2 
DAP12-deficient  BM  chimeric  mice  showed  significantly 
greater proliferation than CD45.1+ WT B cells from the same 
mice (Fig. 2 C). Collectively, these results indicate that DAP12 
in B cells negatively regulates B cell proliferation induced by 
the signals from TLR-9 in a B cell–intrinsic manner.
Enhanced Akt phosphorylation and Bcl-xL expression  
and prolonged survival in DAP12-deficient B cells
We investigated the mechanism by which the lack of DAP12 
expression resulted in enhanced proliferation of B cells in-
duced by signals mediated by BCR or TLR. To determine 
where the DAP12-mediated signal intersects with the BCR 
signaling pathway, we examined the kinetics and magnitude 
of tyrosine phosphorylation of Syk, Akt, and the mitogen- 
activated  protein  kinase  (MAPK)  signaling  molecules  Erk, 
Jnk, and p38 in WT and DAP12-deficient B cells. Although 
WT and DAP12-deficient B cells showed similar kinetics of 
Figure 3.  Enhanced tyrosine phosphorylation of Erk, Akt, and Bcl-xL and prolonged survival in DAP12-deficient B cells. Purified B cells from 
the spleens of WT and DAP12-deficient mice were stimulated with 5 µg/ml of F(ab’)2 fragments of anti–mouse IgM (A and C) or 0.06 µM CpG (B and C).  
(A and B) The stimulated cells were lysed and then analyzed by immunoblotting with antibodies specific for indicated proteins. Bar graphs show the rela-
tive amount of each phosphorylated protein, as determined by densitometry, before and after stimulation. (C) The purified B cells 24 h after stimulation 
were fixed and stained with anti–Bcl-xL and then analyzed by flow cytometry. (D and E) The purified B cells were labeled with CFSE, stimulated with  
10 µg/ml anti–mouse IgM or unstimulated (medium) for 48 h, stained with PI and analyzed by flow cytometry (D). The dead cell population was calculated as 
follows: PI+ cell frequency/PI+ and PI cell frequency in each division peak of CFSE dilution (E). *, P < 0.05. n = 4. Data are representative of five (A), 
three (B), two (C), and four (D) independent experiments. Error bars show SD.JEM Vol. 208, No. 8 
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Enhanced proliferation of MAIR-II–deficient B cells
MAIR-II is expressed on B cells as well as on myeloid cells 
(Yotsumoto et al., 2003; Nakahashi et al., 2007). To determine 
the receptor potentially responsible for DAP12-mediated 
inhibition of B cell proliferation, we generated MAIR-II– 
deficient mice by gene targeting (Fig. S4). Naive MAIR-II– 
deficient mice had normal compositions of lymphoid and 
myeloid cell populations in the spleen, BM, thymus, and 
peritoneal cavity, suggesting that MAIR-II is not required for 
normal hematopoietic cell differentiation.
We purified B cells from the spleens of WT and MAIR-
II–deficient mice and stimulated them with F(ab’)2 fragments 
of anti-IgM mAb or CpG. Similar to the pattern seen in 
DAP12-deficient B cells, the proliferation of MAIR-II–deficient 
B cells was greater than that of WT B cells in response to anti-
IgM mAb and CpG (Fig. 4, A and B), indicating that both 
MAIR-II and DAP12 negatively regulate B cell proliferation 
induced by signals mediated by BCR and TLR-9.
DAP12-coupled MAIR-II inhibits B cell proliferation
To verify that the inhibition of B cell proliferation induced by 
stimulation of BCR and TLR-9 was caused by DAP12, we 
restored the expression of DAP12 in DAP12-deficient B cells 
DAP12-deficient B cells more than in WT B cells, we in-
vestigated the NF-B pathway activation by examining the   
degradation of the inhibitor IB, which serves to retain   
NF-B in the cytoplasm, thereby preventing transcriptional 
activation by NF-B after stimulation with anti-IgM or CpG. 
However, IB was degraded with similar kinetics and was 
present  in  similar  amounts  in WT  and  DAP12-deficient   
B cells after stimulation with anti-IgM and CpG (Fig. S3 B). 
Nonetheless,  we  found  that  Bcl-xL  expression  was  up- 
regulated in DAP12-deficient B cells more than in WT   
B  cells  24  h  after  stimulation  with  anti-IgM  and  CpG   
(Fig. 3 C). We therefore examined whether DAP12-deficient 
B cells showed longer survival after stimulation with anti-
IgM. WT and DAP12-deficient B cells were labeled with 
CFSE, stimulated with anti-IgM for 48 h, and stained with 
propidium iodide (PI). Flow cytometry analyses showed that 
the dead (PI+) cell population in each division fraction of 
CFSE dilution in DAP12-deficient B cells was significantly 
lower than that in WT B cells (Fig. 3, D and E), indicating that 
DAP12-deficient B cells showed longer survival than WT   
B cells after BCR stimulation. These results indicate that 
DAP12 in B cells is involved in survival as well as proliferation 
after BCR stimulation.
Figure 4.  Enhanced proliferation of 
MAIR-II–deficient B cells in response to 
anti-IgM and CpG. B cells were purified from 
the spleens of WT or MAIR-II–deficient mice, 
labeled with CFSE (B) or not (A), and  
stimulated with F(ab’)2 fragments of anti-IgM 
or CpG. Proliferation was analyzed by  
flow cytometry. *, P < 0.05; **, P < 0.01.  
Data are representative of three  
independent experiments.
Figure 5.  DAP12-coupled MAIR-II inhib-
its B cell proliferation. (A) Schematic dia-
gram of the constructs: GFP (control); WT 
DAP12 consisting of extracellular (EX), trans-
membrane (TM), and cytoplasmic (Cy)  
domains followed by GFP (DAP12); and the 
fusion protein consisting of the MAIR-II  
extracellular domain, followed by DAP12  
containing an Ala (A) to Asp (D) substitution 
in the transmembrane domain (TM), followed 
by GFP (MAIR-II/DAP12). (B) Purified DAP12-
deficient B cells were transduced with the 
lentiviral vectors and GFP expression was 
analyzed by flow cytometry. Shaded and open 
histograms indicate untransduced and trans-
duced B cells, respectively. (C and D) The lenti-
viral vector–transduced DAP12-deficient or 
MAIR-II–deficient B cells were stimulated 
with PMA, F(ab’)2 fragments of anti-IgM, or 
CpG and then analyzed for proliferation. Error 
bars show SD. (E) K46 µm cells were trans-
duced with the MAIR-II/DAP12 lentiviral vector, stained with anti–MAIR-II or anti-IgM, and analyzed by flow cytometry (left). K46 µm transfectants 
were stimulated with anti-IgM, and immunoprecipitates with anti–MAIR-II or control Ig were immunoblotted with anti-SHIP, anti–SHP-1, or anti–MAIR-II 
(right). *, P < 0.05; ***, P < 0.001. Data are representative of three independent experiments.1666 DAP12 suppresses B cell–mediated responses | Nakano-Yokomizo et al.
encoding the fusion 
protein consisting of 
the MAIR-II ecto-
domain  fused  to  a 
mutated DAP12 in 
which the aspartic 
acid (D) in the transmembrane portion was substituted with 
an alanine (A; Fig. 5 A). Because DAP12 requires the posi-
tively charged aspartic acid in the transmembrane portion 
for coupling with cell surface receptors containing a nega-
tively charged amino acid (e.g., lysine or arginine) in their 
transmembrane region, the chimeric receptor cannot pair 
with other endogenous DAP12-associated receptors in the 
transduced  DAP12-deficient  cells.  Therefore,  only  the 
MAIR-II  fusion  protein  will  be  capable  of  transmitting 
DAP12-induced  signals. The  efficiencies  of  transduction 
into DAP12-deficient B cells were comparable between 
the control vector and the vector constructed with the chimeric 
cDNA (Fig. 5 B). Similar to the case with the DAP12-restored   
B cells, the proliferation of DAP12-deficient B cells expressing   
by transduction of the Tyrobp cDNA encoding DAP12 with a 
lentivirus vector containing the IRES (internal ribosomal 
entry site) sequence, followed by the sequence encoding en-
hanced (e) GFP (Fig. 5 A). The control lentivirus vector and 
the vector constructed with the Tyrobp cDNA (designated 
DAP12) were successfully transduced into DAP12-deficient 
B cells, as determined by eGFP expression (Fig. 5 B), and the 
transduction  efficiencies  were  comparable.  Proliferation  of 
the DAP12-deficient B cells, in which DAP12 expression was 
restored, was significantly lower than that of control vector-
transduced DAP12-deficient B cells after stimulation with 
either anti-IgM mAb or CpG (Fig. 5 C). In contrast, DAP12-
deficient  B  cells  with  restored  DAP12  expression  showed 
similar proliferation to the control vector-transduced DAP12-
deficient B cells when stimulated with PMA (Fig. 5 C). These 
results indicate that DAP12 inhibits B cell proliferation spe-
cifically induced by the stimulation of BCR and TLR-9.
To determine whether DAP12-coupled MAIR-II nega-
tively regulates B cell proliferation, we constructed a chimeric 
cDNA in the lentivirus vector (designated MAIR-II/DAP12) 
Figure 6.  Enhanced humoral immune 
responses in DAP12-deficient mice.  
(A–H) WT (n ≈ 5–9) and DAP12-deficient (n ≈ 5–9) 
mice were depleted (F–H) or not (A–E) of CD4+ 
T cells and macrophages by injection with anti-
CD4 mAb and Cl2MBP liposomes, as described 
in Fig. S5, and then immunized with NP-CGG 
(A–C) or NP-Ficoll (D–H). 14 (A–C) or 8 (D–H) d 
after the immunization, spleen sections were 
stained with biotinylated PNA, followed by 
Alexa Fluor 594–conjugated streptavidin in 
combination with FITC-conjugated anti-B220 
(A, D, and F). Spleen cells were also stained 
with FITC-conjugated GL7 mAb, biotin-conju-
gated PNA, and APC-conjugated anti-B220, 
followed by PE-conjugated streptavidin, and 
the frequencies of GC B cells (defined as the 
percentage of GL-7+PNA+B220+ cells) were 
determined by flow cytometry (B, E, and G). Sera 
were collected from these mice and analyzed 
for NP-specific antibodies by ELISA (C and H).  
(I and J) Mixed BM chimeric mice were  
generated by adoptive transfer of an equal 
number of BM cells isolated from CD45.1 WT 
mice and CD45.2 DAP12-deficient mice into 
Rag1-deficient mice. The spleen sections from 
the BM chimeric mice 8 d after immunization 
with NP-Ficoll were analyzed by immuno-
histology, as described (I). The spleen cells from 
the same mice after the immunization were 
stained with anti-B220, GL7, biotinylated PNA, 
and either anti-CD45.1 or anti-CD45.2, fol-
lowed by APC-conjugated streptavidin. The 
proportions of CD45.1 WT or CD45.2 DAP12-
deficient B cells in non-GC (GL7PNAB220+) 
or GC (GL7+PNA+B220+) B cells are indicated (J). 
(K) Sera were collected from WT (n = 5) and 
DAP12-deficient (n = 5) mice at the age of 10 
wk old and analyzed for the titer of antibodies 
specific for the self-antigens indicated. The 
horizontal bars show the mean. *, P < 0.05; **, 
P < 0.01; ***, P < 0.001. Data are representative 
of five mice (A, D, and F) and two (B, E, G, I, and J) 
and three (K) independent experiments. Error 
bars show SD.JEM Vol. 208, No. 8 
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as dendritic cells or macrophages, which express DAP12. To 
address whether DAP12 in B cells was involved in the inhibi-
tion of B cell proliferation in vivo, we then used a T cell–
independent (TI) antigen NP-Ficoll, which requires neither 
CD4+ helper T cells nor APC. Although GC formation was 
hardly detected in WT mice, DAP12-deficient mice showed 
significant numbers of GC after immunization with NP-Ficoll 
(Fig. 6 D). Flow cytometric analyses also demonstrated that 
the frequencies of GC B cells were significantly larger in 
DAP12-deficient mice than in WT mice (Fig. 6 E). These re-
sults suggest that DAP12 in B cells inhibits the proliferation of 
GC B cells in response to TI antigen.
To strictly exclude the involvement of DAP12-expressing 
APC in the humoral immune response, we depleted both 
CD4+ T cells and macrophages from WT and DAP12-deficient 
mice by injection with anti-CD4 mAb 2 d before immuniza-
tion and injection with clodronate liposomes 1 d before im-
munization. Flow cytometric analyses demonstrated that the 
numbers of CD4+CD8 cells and CD11b+F4/80+ cells were 
significantly decreased in the spleen after the treatment on 
the day of immunization compared with those in naive mice 
(Fig. S5), indicating that CD4+ helper T cells and macro-
phages were successfully depleted. After depletion, DAP12-
deficient mice had significant numbers of GC in the spleen in 
response to NP-Ficoll (Fig. 6 F), whereas very few GCs were 
observed in WT mice. The frequencies of GC B cells in the 
spleens of DAP12-deficient mice were again significantly 
larger than in WT mice in response to NP-Ficoll (Fig. 6 G). 
Furthermore, we observed that anti-NP IgG3 was generated 
in DAP12-deficient mice at a significantly higher level than 
in WT mice 8 d after immunization with NP-Ficoll (Fig. 6 H).
To  provide  direct  evidence  that  these  phenotypes  ob-
served in DAP12-deficient mice were B cell intrinsic, we 
generated BM chimeric mice by transfer of a 1:1 mixture of 
BM cells from CD45.1+ WT mice and CD45.2+ DAP12- 
deficient mice into Rag1-deficient mice, as described in 
Fig. 2 A. The BM chimeric mice also formed a significant 
number of GC after immunization with NP-Ficoll (Fig. 6 I). 
Flow cytometric analyses demonstrated that the majority of 
GC B cells (GL7+, PNA+, and B220+) were derived from 
CD45.2+ DAP12-deficient BM, whereas the proportions of 
CD45.1+ WT and CD45.2+ DAP12-deficient B cells were 
comparable in the non-GC (GL7, PNA, and B220+) B cells 
(Fig. 6 J), indicating that the enhanced humoral immune re-
sponses  in  DAP12-deficient  mice  were  B  cell  intrinsic.   
Together, these results indicate that DAP12 in B cells inhibits 
proliferation induced by BCR-mediated signals in vivo.
Increased antibodies against self-antigens  
in DAP12-deficient mice
These results led us to examine whether DAP12-deficient 
mice are associated with disorders of humoral immunity.   
We therefore examined the levels of the antibodies against 
self-antigens,  such  as  cardiolipin,  double-strand  (ds)  DNA, 
and histone, in the sera of 10-wk-old WT and DAP12-deficient 
mice. DAP12-deficient mice showed significantly higher 
the MAIR-II/DAP12 fusion protein was significantly lower 
than that of control-transduced DAP12-deficient B cells after 
stimulation with either anti-IgM or CpG (Fig. 5 C). To further 
confirm this observation, we introduced the lentivirus vector 
that encoded the chimeric protein into MAIR-II–deficient 
B cells. The proliferation of MAIR-II–deficient B cells ex-
pressing the chimeric protein was significantly lower than 
that of control vector-transduced MAIR-II–deficient B cells 
after stimulation with anti-IgM mAb or CpG. In contrast, 
there were no differences in proliferation between the control 
vector-transduced MAIR-II–deficient B cells and those ex-
pressing the chimeric protein after stimulation with PMA 
(Fig. 5 D). Collectively, these results provide evidence that 
DAP12-coupled MAIR-II inhibits B cell proliferation specif-
ically induced by the stimulation of BCR and TLR-9.
DAP12 recruits the SH2 domain–containing  
protein tyrosine phosphatase 1 (SHP-1)
To investigate how DAP12 mediates an inhibitory signal in   
B cells, we used a B cell lymphoma line K46 µm that ex-
presses IgM BCR (Wakabayashi et al., 2002). We established 
the K46 µm transfectant stably expressing the MAIR-II/
DAP12 fusion protein (Fig. 5 E). The K46 µm transfectant 
was stimulated with anti-BCR mAb, lysed, and immuno-
precipitated with anti–MAIR-II mAb. SHP-1 was coimmuno-
precipitated with MAIR-II/DAP12 fusion protein 5 min after 
the stimulation (Fig. 5 E). In contrast, the SH2 domain–
containing inositol phosphatase (SHIP) was not coimmuno-
precipitated with the fusion protein. These results suggest that 
DAP12 recruits SHP-1 in B cells after BCR stimulation, which 
may be involved in inhibitory signals in B cells.
Enhanced humoral immune responses  
in DAP12-deficient mice
Because  BCR-mediated  signaling  is  increased  in  DAP12- 
deficient B cells in vitro, we examined whether B cell prolif-
eration induced by antigen stimulation is also increased in 
DAP12-deficient mice. We immunized WT and DAP12- 
deficient mice with the T cell–dependent (TD) antigen NP-CG 
and then, 14 d later, analyzed germinal center (GC) formation 
in the spleen. Immunohistochemical staining of the spleen 
sections with peanut agglutinin (PNA) showed that each GC 
generated in DAP12-deficient mice was larger than that in 
WT mice (Fig. 6 A). In agreement with these results, flow 
cytometric analyses demonstrated that the frequencies of 
GC B cells (as defined by GL7+PNA+B220+ cells) were sig-
nificantly larger in DAP12-deficient mice than in WT mice 
(Fig. 6 B). Moreover, although the antibody titers of IgM and 
IgG1 specific to NP in the sera 14 d after immunization were 
comparable between WT and DAP12-deficient mice, IgG2a 
titers specific to NP were significantly higher in DAP12- 
deficient mice than in WT mice (Fig. 6 C). These results sug-
gest that DAP12 inhibits the proliferation of GC B cells in 
response to TD antigen in mice.
The humoral immune responses against TD antigens are 
dependent on CD4+ helper T cells, which require APC, such 1668 DAP12 suppresses B cell–mediated responses | Nakano-Yokomizo et al.
of BrdU incorporated cells in DAP12-untransduced (GFP) 
B cells was significantly higher than that in DAP12-transduced 
(GFP+) cells (Fig. 7 E). Collectively, these results indicate that 
DAP12 inhibits human B cell proliferation after stimulation 
through TLR-9.
DISCUSSION
In this study, we evaluated the role of the signaling adapter 
protein DAP12 in B cell activation in both humans and mice. 
To further determine the role of DAP12 in B cells, we gener-
ated Cd300d/ mice that lack expression of MAIR-II, an 
immune receptor which had been shown previously to asso-
ciate with DAP12 in B cells (Yotsumoto et al., 2003; Nakahashi 
et al., 2007). Using Cd300d/ mice and DAP12-deficient 
mice, we demonstrated that MAIR-II, through coupling with 
DAP12, inhibits B cell activation and proliferation induced by 
BCR- and TLR-mediated signaling. The inhibition of TLR-
mediated signal by DAP12 in B cells was similar to that ob-
served  in  myeloid  cells  (Hamerman  et  al.,  2005; Turnbull   
et al., 2006). However, our finding that DAP12 also inhibited 
BCR-mediated activation signals was surprising because this 
is the first paper that DAP12 is also involved in antigen-specific 
adaptive  immunity.  Indeed,  DAP12-deficient  mice  showed 
enhanced humoral immune responses against TI antigen NP-
Ficoll even after depletion of CD4+ T cells and macrophages. 
We further demonstrated that the enhanced humoral im-
mune responses in DAP12-deficient mice is B cell intrinsic. 
These results indicate that DAP12 plays an important role in 
antigen-specific immune responses by B cells in vivo.
Previous studies have demonstrated that DAP12-deficient 
mice show several phenotypes, including failure to develop 
autoimmunity (as a result of impaired antigen priming; Bakker   
et al., 2000), impaired hapten-specific contact hypersensitiv-
ity (Tomasello et al., 2000), and osteopetrosis and thalamic   
amounts of these antibodies than WT mice (Fig. 6 K). These 
results suggest that DAP12 negatively regulates the autoanti-
body production in mice.
DAP12 inhibits human B cell proliferation
We examined DAP12 expression in human B cells (CD19+ 
cells) and monocytes (CD14+ cells) sorted to >99.9% purity 
by flow cytometry from PBMC of a healthy donor. The RNA 
was extracted from the purified cells and was subjected to 
semiquantitative RT-PCR for expression of TYROBP and 
GAPDH transcripts, according to template dose by dilution. 
Human B cells expressed TYROBP transcripts, although the 
expression level was much less than that in monocytes (Fig. 7 A). 
Although DAP12 protein expression was scarcely detected in 
resting B cells, stimulation of B cells with anti-IgM or CpG 
up-regulated the expression of DAP12 (Fig. 7 B). Therefore, 
we examined whether DAP12 inhibits B cell proliferation in 
humans. To address this question, we used DAP12-deficient 
B cells from a Japanese patient with Nasu-Hakola disease—a 
recessive genetic disorder—whose TYROBP gene was mu-
tated and DAP12 expression was lacking. When PBMC from 
a healthy donor were stained with anti-DAP12, we detected 
DAP12 expression at a significant level in monocytes. In con-
trast, DAP12 expression was never detected on cells in mono-
cytes when analyzing PBMC from the patient (Fig. 7 C). 
PBMCs from a Nasu-Hakola patient were transduced with a 
lentiviral vector encoding DAP12 and GFP and then stimu-
lated with CpG. After cultures were pulsed with BrdU, PBMCs 
were stained with anti-CD19 and anti-BrdU and then ana-
lyzed for B cell proliferation by flow cytometry, as determined 
by BrdU incorporation in the CD19+ gated B cells. The fre-
quency of BrdU+ cells in DAP12-transduced (GFP+) cells was 
significantly lower than in DAP12-untransduced (GFP) B cells 
(Fig. 7, D and E). Moreover, the mean fluorescence intensity   
Figure 7.  DAP12 inhibits human B cell prolif-
eration. (A) PBMCs derived from a healthy donor 
were stained with PE-conjugated anti-CD19 and FITC-
conjugated anti-CD14 mAbs. CD19+ B cells or CD14+ 
monocytes were sorted to >99.9% purity by flow 
cytometry. The RNA was extracted from the purified 
cells and was subjected to semiquantitative RT-PCR 
for expression of DAP12 and GAPDH transcripts, ac-
cording to template dose by dilution. (B and C) PBMCs 
derived from a healthy donor or a patient with  
Nasu-Hakola disease were stimulated (B) or not (C) 
with anti-IgM or CpG for 48 h and then stained with 
PE-conjugated anti-CD20 (B) or anti-CD14 (C). Cells 
were fixed and then stained with anti-DAP12 (red 
line) or control Ig (black line), followed by FITC-
  conjugated secondary antibody. Plots in B are gated 
on CD20+ cells and plots in C are gated on CD14+ cells.  
(D and E) PBMCs from a patient with Nasu-Hakola 
disease were transduced or not with the lentiviral 
vector encoding DAP12 and EGFP and then stimulated with CpG. BrdU was pulsed for the final 24 h in the culture. Cells were stained with PE-conjugated 
anti-CD19 mAb and then fixed, followed by staining with APC-conjugated anti-BrdU mAb and analyzed for B cell proliferation, as determined by BrdU 
incorporation, on the CD19+ gated cells by flow cytometry (D). The frequencies of BrdU+ cells in GFP and GFP+ cells and mean fluorescence intensity 
(MFI) of BrdU+ cells in GFP and GFP+ cells were determined (E). The data represent two independent experiments (A–E). *, P < 0.05. Error bars show SD.JEM Vol. 208, No. 8 
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that a highly purified B cell population showed enhanced 
proliferation in response to BCR and TLR stimulation in 
vitro, suggesting that an endogenous self-ligand for MAIR-II 
might exist or be inducible on B cells and that cis- or trans-
interactions of MAIR-II with its ligand mediate inhibitory 
signals in B cells.
We showed that the BCR downstream signaling mole-
cules Erk, Akt, and Syk were enhanced for tyrosine phos-
phorylation in DAP12-deficient B cells after stimulation with 
anti-IgM. We also showed that tyrosine phosphorylation of 
Erk and Akt was enhanced after stimulation with CpG in 
DAP12-deficient B cells. Enhanced Erk phosphorylation was 
also reported in DAP12-deficient macrophages after stimula-
tion with LPS (Hamerman et al., 2005). However, the Erk 
phosphorylation was detected as early as 0.5 min in DAP12-
deficient  B  cells  after  stimulation  with  anti-IgM  or  CpG, 
whereas DAP12-deficient macrophages showed Erk phos-
phorylation at 20 min after LPS stimulation (Hamerman et al., 
2005), suggesting that DAP12-mediated inhibitory signaling 
pathways to Erk are different between B cells and macro-
phages. Previous studies demonstrated that PI3K plays a critical 
role in BCR-mediated signaling for cell proliferation and sur-
vival (Suzuki et al., 2003; Srinivasan et al., 2009). We found 
enhanced phosphorylation of Akt, the major downstream 
target of PI3K, in DAP12-deficient B cells after stimulation 
with CpG, as well as with anti-IgM. Moreover, we also found 
enhanced expression of Bcl-xL, which may be directly in-
volved in the increased survival of DAP12-deficient B cells. It 
remains unclear how enhanced Erk or Akt phosphorylation 
causes enhanced Bcl-xL expression in B cells. Further studies 
are required to define the signaling mechanisms by which 
DAP12 mediates inhibitory signals in B cells as well as mye-
loid cells.
MATERIALS AND METHODS
Mice. C57BL/6J mice were purchased from Clea Japan. DAP12-deficient 
(Tyrobp/) mice were backcrossed onto the C57BL/6 genetic background 
for 12 generations as previously described (Kaifu et al., 2003). MAIR-II– 
deficient (Cd300d/) mice were generated in our laboratory and backcrossed 
onto the C57BL/6 genetic background for 12 generations (Fig. S4). All ex-
periments were performed in accordance with the guidelines of the animal 
ethics committee of the University of Tsukuba Animal Research Center.
Human DAP12-deficient B cells. PBMCs were obtained from healthy 
volunteers or a Japanese patient with Nasu-Hakola disease. The patient was 
diagnosed based on the clinical features, including repeated pathological frac-
tures and progressive dementia, characteristic of this disease, and the mutation 
of the TYROBP gene encoding DAP12, which had a homozygous single-base 
deletion in exon 3 that caused a frame shift, resulting in a premature stop codon 
(Paloneva et al., 2000). All experiments using human blood cells from healthy 
volunteers and a patient with Nasu-Hakola disease were approved by the 
ethics committee in medicine at the University of Tsukuba, and we obtained 
informed consents according to the committee guideline before the study.
Antibodies. MAbs against mouse CD80, CD86, I-Ab, CD40, B220, IgD, 
IgM, CD11b, CD23, CD38, AA4, and CD25 and human CD19 and CD14 
were purchased from BD. MAbs against mouse Fas and CD45.1 were pur-
chased from eBioscience. Anti-CD45.2 mAb was purchased from BioLeg-
end. Anti–human DAP12 mAb (DX37) was provided by J. Phillips (Merck 
Laboratories).  Anti–phospho-Syk,  anti-Syk,  anti–phospho-Akt,  anti-Akt, 
hypomyelinosis (Kaifu et al., 2003), but humoral immune re-
sponses were not tested in these prior studies. We showed 
that the antibodies against self-antigens, such as cardiolipin, 
dsDNA, and histone, were elevated in the sera of 10-wk-old 
DAP12-deficient mice, suggesting the possible involvement 
of DAP12 in the development of antibody-mediated autoim-
mune diseases. There are few studies on the immunological 
function of patients with Nasu-Hakola disease. This is the first 
study on the role of the immunoreceptor adapter protein 
DAP12 in B cell activation in both humans and mice. The 
pathophysiological significance of the involvement of DAP12 
in humoral immune responses should be studied further, pref-
erably by using B cell–specific DAP12-deficient mice and by 
a careful examination of the immune system in patients with 
this disease.
We demonstrated that MAIR-II, through coupling with 
DAP12, inhibits B cell activation induced by stimulation of 
BCR and TLR. It is not clear, however, if MAIR-II is the 
only partner of DAP12 involved in the inhibitory effect on 
B cell activation. We did not observe an enhanced humoral 
immune response in MAIR-II–deficient mice, which was ob-
served in the DAP12-deficient mice, suggesting that DAP12-
coupled receptors other than MAIR-II might also suppress   
B cell responses. Indeed, numerous receptors have been iden-
tified that associate with DAP12 in broad cell types (Turnbull 
and Colonna, 2007; Lanier, 2009), but it has not thoroughly 
been examined whether each receptor is also expressed on   
B cells. It is also possible that novel immunoreceptors that as-
sociate with DAP12 are expressed on B cells. Identification of 
DAP12-coupled immunoreceptors other than MAIR-II ex-
pressed on B cells is required to determine the mechanism of 
DAP12-mediated inhibition of humoral immune responses. 
Alternatively, because MAIR-II is expressed by myeloid cells, 
as well as B cells, MAIR-II–deficient myeloid cells might   
affect B cell responses in MAIR-II–deficient mice.
The signaling pathways involved in DAP12-mediated in-
hibition are not completely understood (Hamerman and 
Lanier, 2006; Turnbull and Colonna, 2007). A recent report 
demonstrated that SHIP was recruited to DAP12 after liga-
tion of TREM-2 and it inhibits TREM-2 and DAP12 sig-
naling in a macrophage cell line (Peng et al., 2010). On the 
contrary,  we  found  that  MAIR-II–associated  DAP12  re-
cruited SHP-1, but not SHIP, in a B cell line after stimulation 
with anti-BCR mAb. Pasquier et al. (2005) have shown that 
binding of monomeric IgA to the FcR-associated FcRI 
receptor (CD89) recruits SHP-1, which suppresses immune 
responses, whereas aggregated multimeric IgA complexes 
cause cellular activation through the recruitment and acti-
vation of Syk. These results suggest that the outcome (i.e., 
whether DAP12 functions as a suppressor or activator) might 
be influenced by the affinity or avidity of the interaction be-
tween the DAP12-associated receptor and its ligand. There-
fore, the nature of the ligand, its receptor, and the cell type 
may all be important in determining whether DAP12 func-
tions in positive or negative signaling. At present, a ligand for 
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Humoral immune responses. Mice were injected i.p. with 10 µg NP-CG 
emulsified with alum or 10 µg NP-Ficoll (Biosearch Technologies) in PBS. 
For GC staining, spleen sections were stained with biotinylated PNA (Vector 
Laboratories), followed by Alexa Fluor 594–conjugated streptavidin in com-
bination with FITC-conjugated anti-B220 mAb. For analyses of GC B cell 
number, splenocytes were stained with FITC-conjugated GL7 mAb, biotin-
conjugated  PNA,  and APC-conjugated  anti-B220,  followed  with  PE-
conjugated streptavidin, and then analyzed by flow cytometry. Sera were 
collected before and 8 or 14 d after the immunization and assayed for anti-
NP IgM, IgG1, and/or IgG3 by ELISA, as previously described (Honda et al., 
2009). For in vivo depletion of CD4+ T cells, mice were injected i.p with 
100 µg anti-CD4 mAb (GK1.5) 2 d before immunization, as previously de-
scribed (Honda et al., 2009). For in vivo depletion of macrophages, mice 
were injected i.p. with 500 µl liposomes encapsulating dichloromethylene 
bisphosphonate (Cl2MBP-liposomes) (Encapsula NanoSciences) 1 d before   
immunization, as previously described (Van Rooijen, 1989). Autoanti-
bodies against cardiolipin (Sigma-Aldrich), dsDNA (Sigma-Aldrich), and 
histone (Roche) were determined by ELISA.
Statistics. Statistical analyses were performed with the unpaired Student’s   
t test. P-values <0.05 were considered statistically significant.
Online supplemental material. Fig. S1 shows enhanced proliferation of 
DAP12-deficient follicular, marginal zone, and transitional B cell subsets in 
response to BCR stimulation. Fig. S2 demonstrates that maturation and acti-
vation markers of B cells derived from WT and DAP12-deficient mice are 
comparable. Fig. S3 shows comparable IKB degradation in WT and DAP12-
deficient B cells after stimulation with anti-IgM or CpG. Fig. S4 shows a tar-
geting vector for disruption of the MAIR-II gene. Fig. S5 shows depletion of 
CD4+ T cells and macrophages. Online supplemental materials are available 
at http://www.jem.org/cgi/content/full/jem.20101623/DC1.
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